Information on EC 2.4.1.133 - xylosylprotein 4-beta-galactosyltransferase

Word Map on EC 2.4.1.133
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Select one or more organisms in this record:
Show additional data
Do not include text mining results
Include (text mining) results (more...)
Include results (AMENDA + additional results, but less precise; more...)

The enzyme appears in viruses and cellular organisms

EC NUMBER
COMMENTARY hide
2.4.1.133
-
RECOMMENDED NAME
GeneOntology No.
xylosylprotein 4-beta-galactosyltransferase
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
UDP-alpha-D-galactose + O-beta-D-xylosyl-[protein] = UDP + 4-beta-D-galactosyl-O-beta-D-xylosyl-[protein]
show the reaction diagram
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
hexosyl group transfer
PATHWAY
BRENDA Link
KEGG Link
MetaCyc Link
Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfate
-
-
Glycosaminoglycan biosynthesis - heparan sulfate / heparin
-
-
glycosaminoglycan-protein linkage region biosynthesis
-
-
Metabolic pathways
-
-
SYSTEMATIC NAME
IUBMB Comments
UDP-galactose:O-beta-D-xylosylprotein 4-beta-D-galactosyltransferase
Involved in the biosynthesis of the linkage region of glycosaminoglycan chains as part of proteoglycan biosynthesis (chondroitin, dermatan and heparan sulfates). Requires Mn2+.
CAS REGISTRY NUMBER
COMMENTARY hide
52227-72-2
-
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
malfunction
-
an antibody against beta-1,4-GalT-I attenuates both lipopolysaccharide-induced microglial activation and phagocytosis
physiological function
additional information
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
4-nitrophenyl beta-D-xylopyranoside + UDP-alpha-D-galactose
UDP + 4-nitrophenyl 4-O-beta-D-galactopyranosyl-beta-D-xylopyranoside
show the reaction diagram
-
-
-
-
?
UDP-alpha-D-galactose + 2-naphthyl ?-D-xylopyranoside
UDP + 4-beta-D-galactosyl-2-naphthyl-beta-D-xylospyranoside
show the reaction diagram
-
-
-
-
?
UDP-alpha-D-galactose + 4-methylumbelliferyl alpha-D-xylopyranoside
UDP + 4-methylumbelliferyl 4-O-beta-D-galactopyranosyl-beta-D-xylopyranoside
show the reaction diagram
-
-
-
?
UDP-alpha-D-galactose + 4-methylumbelliferyl beta-D-xylopyranoside
UDP + 4-methylumbelliferyl 4-O-beta-D-galactopyranosyl-beta-D-xylopyranoside
show the reaction diagram
-
-
-
-
?
UDP-alpha-D-galactose + 4-methylumbelliferyl-beta-D-xylopyranoside
UDP + ?
show the reaction diagram
the strategic position of Tyr194 forming stacking interactions with the aglycone, and the hydrogen bond between the His195 nitrogen backbone and the carbonyl group of the coumarinyl molecule to develop a tight binder of the enzyme. This leads to the synthesis of 4-deoxy-4-fluoroxylose linked to 4-methylumbelliferone that inhibits enzyme activity in vitro with a Ki 10 times lower than the Km value and efficiently impairs glycosaminoglycan synthesis in a cell assay. Molecular modeling of the enzyme's active site in the presence of UDP-alpha-D-galactose and 4-methylumbelliferyl-beta-D-xylopyranoside using the crystal structure of Drosophila melanogaster enzyme dbeta4GalT7, PDB code 4M4K, overview
-
-
?
UDP-alpha-D-galactose + D-xylose
UDP + 4-O-beta-D-galactosyl-beta-D-xylose
show the reaction diagram
UDP-alpha-D-galactose + O-beta-D-xylosyl-[protein]
UDP + 4-beta-D-galactosyl-O-beta-D-xylosyl-[protein]
show the reaction diagram
UDP-alpha-D-galactose + xylobiose
UDP + ?
show the reaction diagram
-
-
-
?
UDP-galactose + 2-(6-hydroxynaphthyl) beta-D-xylopyranoside
?
show the reaction diagram
-
-
-
-
?
UDP-galactose + 3-acetamido-propyl beta-D-xylopyranoside
?
show the reaction diagram
-
-
-
-
?
UDP-galactose + 3-benzamido-propyl beta-D-xylopyranoside
?
show the reaction diagram
-
-
-
-
?
UDP-galactose + 3-hexanamido-propyl beta-D-xylopyranoside
?
show the reaction diagram
-
-
-
-
?
UDP-galactose + 4-methylumbelliferyl O-beta-D-xylopyranoside
UDP + 4-methylumbelliferyl 4-O-beta-D-galacto-pyranosyl-beta-D-xylopyranoside
show the reaction diagram
-
-
-
-
?
UDP-galactose + 4-methylumbelliferyl O-beta-D-xylopyranoside
UDP + 4-methylumbelliferyl 4-O-beta-D-galactopyranosyl-beta-D-xylopyranoside
show the reaction diagram
-
-
-
-
?
UDP-galactose + 4-methylumbelliferyl O-beta-D-xylopyranoside
UDP + 4-methylumbelliferyl 4-O-beta-D-galactopyranoyl-beta-D-xylopyranoside
show the reaction diagram
-
-
-
-
?
UDP-galactose + 4-methylumbelliferyl-beta-D-xylopyranoside
?
show the reaction diagram
-
-
-
-
?
UDP-galactose + 4-nitrophenyl O-beta-D-xylopyranoside
UDP + 4-nitrophenyl 4-O-beta-D-galacto-pyranosyl-beta-D-xylopyranoside
show the reaction diagram
-
-
-
-
?
UDP-galactose + 4-nitrophenyl O-beta-D-xylopyranoside
UDP + 4-nitrophenyl 4-O-beta-D-galactopyranosyl-beta-D-xylopyranoside
show the reaction diagram
-
-
-
-
?
UDP-galactose + N-[O-(beta-D-xylopyranosyl)-3-hydroxypropyl]phthalamate
?
show the reaction diagram
-
-
-
-
?
UDP-galactose + N-[O-(beta-D-xylopyranosyl)-3-hydroxypropyl]succinamate
?
show the reaction diagram
-
-
-
-
?
UDP-galactose + O-beta-D-xylosylprotein
UDP + 4-beta-D-galactosyl-O-beta-D-xylosylprotein
show the reaction diagram
UDP-galactose + O-gamma-2,3,4-tri-O-acetyl-(beta-D-xylopyranosyl)-N-Cbz-L-serine methyl ester
?
show the reaction diagram
-
-
-
-
?
UDP-galactose + O-gamma-beta-D-xylopyranosyl-N-Cbz-L-serine methyl ester
?
show the reaction diagram
-
-
-
-
?
UDP-galactose + p-nitrophenyl-beta-D-xyloside
UDP + Galbeta(1-4)Xylbeta-p-nitrophenyl
show the reaction diagram
-
-
-
-
?
UDP-glucose + 4-methylumbelliferyl-beta-D-xylopyranoside
?
show the reaction diagram
-
-
-
?
UDP-glucuronic acid + 4-methylumbelliferyl-beta-D-xylopyranoside
?
show the reaction diagram
-
-
-
?
UDP-N-acetyl glucosamine + 4-methylumbelliferyl-beta-D-xylopyranoside
?
show the reaction diagram
-
-
-
?
UDP-xylose + 4-methylumbelliferyl-beta-D-xylopyranoside
?
show the reaction diagram
-
-
-
?
UDPgalactose + 4-methylumbelliferyl-beta-D-xyloside
UDP + beta-D-galactosyl-1,4-beta-D-xylosyl-1-O-(4-methylumbelliferone)
show the reaction diagram
UDPgalactose + beta-galactosyl-1,4-N-acetyl-beta-D-glucosaminyl-1,6-(N-acetyl-beta-D-glucosaminyl-1,2)-alpha-D-mannosyl-1,6-beta-D-mannosyl-octyl
UDP + beta-D-galactosyl-1,4-beta-galactosyl-1,4-N-acetyl-beta-D-glucosaminyl-1,6-(N-acetyl-beta-D-glucosaminyl-1,2)-alpha-D-mannosyl-1,6-beta-D-mannosyl-octyl
show the reaction diagram
-
-
-
-
?
UDPgalactose + N-acetyl-beta-D-glucosamine
UDP + beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosamine
show the reaction diagram
UDPgalactose + N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1,6-beta-D-mannosyl-octyl
UDP + beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1,6-beta-D-mannosyl-octyl
show the reaction diagram
-
-
-
-
?
UDPgalactose + N-acetyl-beta-D-glucosaminyl-1,6-(beta-galactosyl-1,4-N-acetyl-beta-D-glucosaminyl-1,2)-alpha-D-mannosyl-1,6-beta-D-mannosyl-octyl
UDP + beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosaminyl-1,6-(beta-galactosyl-1,4-N-acetyl-beta-D-glucosaminyl-1,2)-alpha-D-mannosyl-1,6-beta-D-mannosyl-octyl
show the reaction diagram
-
-
-
-
?
UDPgalactose + N-acetyl-beta-D-glucosaminyl-1,6-(N-acetyl-beta-D-glucosaminyl-1,2)-alpha-D-mannosyl-1,6-beta-D-mannosyl-octyl
UDP + beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosaminyl-1,6-(N-acetyl-beta-D-glucosaminyl-1,2)-alpha-D-mannosyl-1,6-beta-D-mannosyl-octyl
show the reaction diagram
-
-
-
-
?
UDPgalactose + N-acetyl-beta-D-glucosaminyl-1,6-alpha-D-mannosyl-1,6-beta-D-mannosyl-octyl
UDP + beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosaminyl-1,6-alpha-D-mannosyl-1,6-beta-D-mannosyl-octyl
show the reaction diagram
-
-
-
-
?
UDPgalactose + O-beta-D-xylosylprotein
UDP + 4-beta-D-galactosyl-O-beta-D-xylosylprotein
show the reaction diagram
UDPgalactose + p-nitrophenyl beta-D-xylopyranoside
UDP + beta-D-galactopyranosyl-1,4-xylopyranosyl-1-O-nitrophenol
show the reaction diagram
UDPgalactose + p-nitrophenyl beta-D-xylose
UDP + beta-D-galactosyl-1,4-beta-D-xylosyl-1-O-nitrophenol
show the reaction diagram
-
-
-
-
?
UDPgalactose + p-nitrophenyl N-acetyl-beta-D-glucosaminide
UDP + beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosaminide-1-O-nitrophenol
show the reaction diagram
-
-
-
-
?
UDPgalactose + xylosylserine
UDP + beta-D-galactosyl-1,4-beta-D-xylosylserine
show the reaction diagram
-
-
-
-
?
additional information
?
-
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
UDP-alpha-D-galactose + 2-naphthyl ?-D-xylopyranoside
UDP + 4-beta-D-galactosyl-2-naphthyl-beta-D-xylospyranoside
show the reaction diagram
-
-
-
-
?
UDP-alpha-D-galactose + O-beta-D-xylosyl-[protein]
UDP + 4-beta-D-galactosyl-O-beta-D-xylosyl-[protein]
show the reaction diagram
UDP-galactose + O-beta-D-xylosylprotein
UDP + 4-beta-D-galactosyl-O-beta-D-xylosylprotein
show the reaction diagram
UDPgalactose + N-acetyl-beta-D-glucosamine
UDP + beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosamine
show the reaction diagram
-
-
-
-
-
UDPgalactose + O-beta-D-xylosylprotein
UDP + 4-beta-D-galactosyl-O-beta-D-xylosylprotein
show the reaction diagram
additional information
?
-
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
Co2+
-
slightly activation
Ni2+
-
very slightly activation
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
1,4-diamino-2,3-dicyano-1,4-bis-(2-aminophenylthio)butadiene
-
0-10 microM of specific inhibitor U0126 of MAP kinase cascade inhibits beta-1,4-GalT I mRNA production induced by lipopolysaccharide
2-(6-hydroxynaphthyl) beta-D-xylopyranoside
-
-
3-acetamido-propyl beta-D-xylopyranoside
-
-
3-benzamido-propyl beta-D-xylopyranoside
-
-
3-hexanamido-propyl beta-D-xylopyranoside
-
-
4-methylumbelliferyl 4-deoxy-beta-D-fluoroxylose
-
-
4-methylumbelliferyl 4-deoxy-beta-D-xylopyranoside
-
4-methylumbelliferyl 4-deoxyxylose
-
-
4-methylumbelliferyl 4-fluoro-beta-D-xylopyranoside
50% inhibition at 2 mM. The strategic position of Tyr194 forming stacking interactions with the aglycone, and the hydrogen bond between the His195 nitrogen backbone and the carbonyl group of the coumarinyl molecule to develop a tight binder of the enzyme. This leads to the synthesis of 4-deoxy-4-fluoroxylose linked to 4-methylumbelliferone that inhibits enzyme activity in vitro with a Ki 10 times lower than the Km value and efficiently impairs glycosaminoglycan synthesis in a cell assay
-
4-[4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazol-2-yl] phenol
-
10-30 microM of specific inhibitor SB202190 of MAP kinase cascade inhibits beta-1,4-GalT I mRNA production induced by lipopolysaccharide
cycloheximide
-
first order kinetics
N-[O-(beta-D-xylopyranosyl)-3-hydroxypropyl]phthalamate
-
-
N-[O-(beta-D-xylopyranosyl)-3-hydroxypropyl]succinamate
-
-
naphthyl 4-deoxy-beta-D-xylopyranoside
slight inhibition
-
O-gamma-beta-D-xylopyranosyl-N-Cbz-L-serine methyl ester
-
-
pyrazolanthrone
-
10-50 microM of specific inhibitor SP600125 of MAP kinase cascade inhibits beta-1,4-GalT I mRNA production induced by lipopolysaccharide
UDP-mannose
-
-
UDP-N-acetylgalactosamine
-
-
additional information
not inhibited by naphthyl 4-deoxy-beta-D-xylopyranoside; structure-guided design of enzyme inhibitors, xyloside inhibitors design and in vitro and in cellulo competition assays, overview
-
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
ATP
-
results suggest that a protein kinase in the 100000 x g supernatant activates galactosyltransferase I
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.58
2-(6-hydroxynaphthyl) beta-D-xylopyranoside
-
recombinant enzyme, in sodium acetate buffer (25 mM, pH 5.0), 20 mM MnCl2, 50 mM KCl, at 25°C
0.75
3-acetamido-propyl beta-D-xylopyranoside
-
recombinant enzyme, in sodium acetate buffer (25 mM, pH 5.0), 20 mM MnCl2, 50 mM KCl, at 25°C
0.53
3-benzamido-propyl beta-D-xylopyranoside
-
recombinant enzyme, in sodium acetate buffer (25 mM, pH 5.0), 20 mM MnCl2, 50 mM KCl, at 25°C
0.75
3-hexanamido-propyl beta-D-xylopyranoside
-
recombinant enzyme, in sodium acetate buffer (25 mM, pH 5.0), 20 mM MnCl2, 50 mM KCl, at 25°C
0.35 - 1.06
4-methylumbelliferyl alpha-D-xylopyranoside
-
0.27 - 4.22
4-methylumbelliferyl O-beta-D-xylopyranoside
0.16 - 4.22
4-methylumbelliferyl-beta-D-xylopyranoside
0.33 - 0.5
4-methylumbelliferyl-beta-D-xyloside
1.27 - 7.93
4-nitrophenyl O-beta-D-xylopyranoside
0.85 - 7.93
4-nitrophenyl-beta-D-xylopyranoside
1.41
beta-galactosyl-1,4-N-acetyl-beta-D-glucosaminyl-1,6-(N-acetyl-beta-D-glucosaminyl-1,2)-alpha-D-mannosyl-1,6-beta-D-mannosyl-octyl
-
pH 7, 37°C
0.91
N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1,6-beta-D-mannosyl-octyl
-
pH 7, 37°C
2.29
N-acetyl-beta-D-glucosaminyl-1,6-(beta-galactosyl-1,4-N-acetyl-beta-D-glucosaminyl-1,2)-alpha-D-mannosyl-1,6-beta-D-mannosyl-octyl
-
pH 7, 37°C
0.33
N-acetyl-beta-D-glucosaminyl-1,6-(N-acetyl-beta-D-glucosaminyl-1,2)-alpha-D-mannosyl-1,6-beta-D-mannosyl-octyl
-
pH 7, 37°C
0.88
N-acetyl-beta-D-glucosaminyl-1,6-alpha-D-mannosyl-1,6-beta-D-mannosyl-octyl
-
pH 7, 37°C
0.4
N-[O-(beta-D-xylopyranosyl)-3-hydroxypropyl]phthalamate
-
recombinant enzyme, in sodium acetate buffer (25 mM, pH 5.0), 20 mM MnCl2, 50 mM KCl, at 25°C
0.56
N-[O-(beta-D-xylopyranosyl)-3-hydroxypropyl]succinamate
-
recombinant enzyme, in sodium acetate buffer (25 mM, pH 5.0), 20 mM MnCl2, 50 mM KCl, at 25°C
0.53
O-gamma-beta-D-xylopyranosyl-N-Cbz-L-serine methyl ester
-
recombinant enzyme, in sodium acetate buffer (25 mM, pH 5.0), 20 mM MnCl2, 50 mM KCl, at 25°C
1.2
p-nitrophenyl beta-D-xylose
-
37°C
0.22 - 0.4
UDP-alpha-D-galactose
0.02 - 2.41
UDP-galactose
0.28
UDP-glucose
-
in 100 mM cacodylate buffer, pH 7.0 containing 10 mM MnCl2 and 0.2-6 microM purified fusion-beta1,4-GalT7
0.13
UDP-xylose
-
in 100 mM cacodylate buffer, pH 7.0 containing 10 mM MnCl2 and 0.2-6 microM purified fusion-beta1,4-GalT7
0.05 - 0.41
UDPgalactose
additional information
additional information
-
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
152
2-(6-hydroxynaphthyl) beta-D-xylopyranoside
Homo sapiens
-
recombinant enzyme, in sodium acetate buffer (25 mM, pH 5.0), 20 mM MnCl2, 50 mM KCl, at 25°C
30.2
3-acetamido-propyl beta-D-xylopyranoside
Homo sapiens
-
recombinant enzyme, in sodium acetate buffer (25 mM, pH 5.0), 20 mM MnCl2, 50 mM KCl, at 25°C
47.2
3-benzamido-propyl beta-D-xylopyranoside
Homo sapiens
-
recombinant enzyme, in sodium acetate buffer (25 mM, pH 5.0), 20 mM MnCl2, 50 mM KCl, at 25°C
41
3-hexanamido-propyl beta-D-xylopyranoside
Homo sapiens
-
recombinant enzyme, in sodium acetate buffer (25 mM, pH 5.0), 20 mM MnCl2, 50 mM KCl, at 25°C
0.13 - 4080
4-methylumbelliferyl-beta-D-xylopyranoside
5460
4-nitrophenyl-beta-D-xylopyranoside
Homo sapiens
-
recombinant maltose-binding protein-beta1,4-GalT7 fusion protein
78.7
N-[O-(beta-D-xylopyranosyl)-3-hydroxypropyl]phthalamate
Homo sapiens
-
recombinant enzyme, in sodium acetate buffer (25 mM, pH 5.0), 20 mM MnCl2, 50 mM KCl, at 25°C
64.3
N-[O-(beta-D-xylopyranosyl)-3-hydroxypropyl]succinamate
Homo sapiens
-
recombinant enzyme, in sodium acetate buffer (25 mM, pH 5.0), 20 mM MnCl2, 50 mM KCl, at 25°C
106.3
O-gamma-beta-D-xylopyranosyl-N-Cbz-L-serine methyl ester
Homo sapiens
-
recombinant enzyme, in sodium acetate buffer (25 mM, pH 5.0), 20 mM MnCl2, 50 mM KCl, at 25°C
0.5 - 1.93
UDP-alpha-D-galactose
0.028 - 5086
UDP-galactose
72
UDP-glucose
Homo sapiens
-
in 100 mM cacodylate buffer, pH 7.0 containing 10 mM MnCl2 and 0.2-6 microM purified fusion-beta1,4-GalT7
3 - 6
UDP-xylose
Homo sapiens
-
in 100 mM cacodylate buffer, pH 7.0 containing 10 mM MnCl2 and 0.2-6 microM purified fusion-beta1,4-GalT7
additional information
UDP-glucuronic acid
kcat/KM VALUE [1/mMs-1]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
52.1
2-(6-hydroxynaphthyl) beta-D-xylopyranoside
Homo sapiens
-
recombinant enzyme, in sodium acetate buffer (25 mM, pH 5.0), 20 mM MnCl2, 50 mM KCl, at 25°C
19702
54.7
3-acetamido-propyl beta-D-xylopyranoside
Homo sapiens
-
recombinant enzyme, in sodium acetate buffer (25 mM, pH 5.0), 20 mM MnCl2, 50 mM KCl, at 25°C
19696
148.5
3-benzamido-propyl beta-D-xylopyranoside
Homo sapiens
-
recombinant enzyme, in sodium acetate buffer (25 mM, pH 5.0), 20 mM MnCl2, 50 mM KCl, at 25°C
19699
85.7
3-hexanamido-propyl beta-D-xylopyranoside
Homo sapiens
-
recombinant enzyme, in sodium acetate buffer (25 mM, pH 5.0), 20 mM MnCl2, 50 mM KCl, at 25°C
19697
0.47 - 4.17
4-methylumbelliferyl alpha-D-xylopyranoside
210593
0.35 - 4.12
4-methylumbelliferyl O-beta-D-xylopyranoside
5877
0.17 - 5.42
4-methylumbelliferyl-beta-D-xylopyranoside
1890
0.13 - 1.32
4-nitrophenyl O-beta-D-xylopyranoside
15351
265.7
N-[O-(beta-D-xylopyranosyl)-3-hydroxypropyl]phthalamate
Homo sapiens
-
recombinant enzyme, in sodium acetate buffer (25 mM, pH 5.0), 20 mM MnCl2, 50 mM KCl, at 25°C
19700
84.3
N-[O-(beta-D-xylopyranosyl)-3-hydroxypropyl]succinamate
Homo sapiens
-
recombinant enzyme, in sodium acetate buffer (25 mM, pH 5.0), 20 mM MnCl2, 50 mM KCl, at 25°C
19698
286.8
O-gamma-beta-D-xylopyranosyl-N-Cbz-L-serine methyl ester
Homo sapiens
-
recombinant enzyme, in sodium acetate buffer (25 mM, pH 5.0), 20 mM MnCl2, 50 mM KCl, at 25°C
19701
1.47 - 7.08
UDP-alpha-D-galactose
891
0.48 - 5.43
UDP-galactose
129
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.3
2-(6-hydroxynaphthyl) beta-D-xylopyranoside
-
recombinant enzyme, in sodium acetate buffer (25 mM, pH 5.0), 20 mM MnCl2, 50 mM KCl, at 25°C
3.69
3-acetamido-propyl beta-D-xylopyranoside
-
recombinant enzyme, in sodium acetate buffer (25 mM, pH 5.0), 20 mM MnCl2, 50 mM KCl, at 25°C
1.04
3-benzamido-propyl beta-D-xylopyranoside
-
recombinant enzyme, in sodium acetate buffer (25 mM, pH 5.0), 20 mM MnCl2, 50 mM KCl, at 25°C
2.46
3-hexanamido-propyl beta-D-xylopyranoside
-
recombinant enzyme, in sodium acetate buffer (25 mM, pH 5.0), 20 mM MnCl2, 50 mM KCl, at 25°C
0.03
4-methylumbelliferyl 4-deoxy-beta-D-fluoroxylose
at pH 7.0 and 37°C
-
0.53
4-methylumbelliferyl 4-deoxy-beta-D-xylopyranoside
pH 7.0, 37°C, recombinant wild-type enzyme
0.53
4-methylumbelliferyl 4-deoxyxylose
at pH 7.0 and 37°C
-
0.03
4-methylumbelliferyl 4-fluoro-beta-D-xylopyranoside
pH 7.0, 37°C, recombinant wild-type enzyme
-
0.61
N-[O-(beta-D-xylopyranosyl)-3-hydroxypropyl]phthalamate
-
recombinant enzyme, in sodium acetate buffer (25 mM, pH 5.0), 20 mM MnCl2, 50 mM KCl, at 25°C
3.96
N-[O-(beta-D-xylopyranosyl)-3-hydroxypropyl]succinamate
-
recombinant enzyme, in sodium acetate buffer (25 mM, pH 5.0), 20 mM MnCl2, 50 mM KCl, at 25°C
2.39
O-gamma-beta-D-xylopyranosyl-N-Cbz-L-serine methyl ester
-
recombinant enzyme, in sodium acetate buffer (25 mM, pH 5.0), 20 mM MnCl2, 50 mM KCl, at 25°C
1.93
TDP
-
UDP-galactose 0.1-16 mM, TDP 0-4 mM
0.61
UDP
-
UDP-galactose 0.1-16 mM, UDP 0-2 mM
1.65
UTP
-
UDP-galactose 0.1-16 mM, UTP 0-4 mM
additional information
CDP
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.06
4-methylumbelliferyl 4-deoxy-beta-D-fluoroxylose
Homo sapiens
Q9UBV7
at pH 7.0 and 37°C
-
1.28
4-methylumbelliferyl 4-deoxy-beta-D-xylopyranoside
Homo sapiens
Q9UBV7
pH 7.0, 37°C, recombinant wild-type enzyme
1.28
4-methylumbelliferyl 4-deoxyxylose
Homo sapiens
Q9UBV7
at pH 7.0 and 37°C
-
0.06
4-methylumbelliferyl 4-fluoro-beta-D-xylopyranoside
Homo sapiens
Q9UBV7
pH 7.0, 37°C, recombinant wild-type enzyme
-
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
0.058
-
maltose-binding protein-fusion enzyme, supernatant, in 100 mM cacodylate buffer containing 10 mM MnCl2, pH 7.0
0.97
-
maltose-binding protein-fusion enzyme, amylose elution, in 100 mM cacodylate buffer containing 10 mM MnCl2, pH 7.0
1.9
-
the protA-tagged beta4GalT
240
-
transgenic line: beta4GalT[-1270/-619]LacZ-930
400
-
transgenic line: beta4GalT[-1085/-628]LacZ-641 and beta4GalT[-756/-743]LacZ-377
600
-
nontransgenic
650
-
transgenic line: beta4GalT[-1270/-619]LacZ-915 and beta4GalT[-1085/-474]LacZ-310
700
-
transgenic line: beta4GalT[-1085/-628]LacZ-642
800
-
transgenic line: beta4GalT[-1085/-628]LacZ-648
1400
-
transgenic line: beta4GalT[-756/-743]LacZ-2226
2400
-
transgenic line: beta4GalT[-756/-743]LacZ-378
2600
-
transgenic line: beta4GalT[-756/-743]LacZ-2211
3300
-
transgenic line: beta4GalT[-756/-743]LacZ-380
4000
-
transgenic line: beta4GalT[-756/-743]LacZ-374
4200
-
transgenic line: beta4GalT[-756/-743]LacZ-369
5500
-
transgenic line: beta4GalT[-793/-707]LacZ-330
6700
-
transgenic line: beta4GalT[-793/-707]LacZ-349
43000
-
transgenic line: beta4GalT[-1085/-628]LacZ-42
45000
-
transgenic line: beta4GalT[-1085/-474]LacZ-328
47000
-
transgenic line: beta4GalT[-1270/-619]LacZ-923
49000
-
transgenic line: beta4GalT[-1270/-474]LacZ-140
50000
-
transgenic line: beta4GalT[-1085/-474]LacZ-330 and beta4GalT[-1085/-474]LacZ-346
53000
-
transgenic line: beta4GalT[-1085/-628]LacZ-58
56000
-
transgenic line: beta4GalT[-793/-707]LacZ-320
68000
-
transgenic line: beta4GalT[-793/-707]LacZ-337
161000
-
transgenic line: beta4GalT[-793/-707]LacZ-339
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
SOURCE
-
-
Manually annotated by BRENDA team
-
in the lesion site after spinal cord injury
Manually annotated by BRENDA team
-
sceletal
Manually annotated by BRENDA team
-
in the lesion site after spinal cord injury
Manually annotated by BRENDA team
-
in the lesion site after spinal cord injury
Manually annotated by BRENDA team
-
mixed neuron-glial cultures prepared from the brains of embryonic days 16-17 rats
Manually annotated by BRENDA team
-
human uterine epithelial cells
Manually annotated by BRENDA team
-
round spermatid
Manually annotated by BRENDA team
-
pachytene spermatocyte
Manually annotated by BRENDA team
-
in the lesion site after spinal cord injury
Manually annotated by BRENDA team
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY hide
GeneOntology No.
LITERATURE
SOURCE
-
type II membrane-bound protein
-
Manually annotated by BRENDA team
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
37000
-
SDS-PAGE
39000
x * 39000, glycosylated recombinant enzyme, SDS-PAGE; x * 39000, SDS-PAGE
55000
-
gel filtration
70000
-
recombinant fusion protein, by SDS-PAGE
71000
-
x * 71000, SDS-PAGE
SUBUNITS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
POSTTRANSLATIONAL MODIFICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
glycoprotein
Crystallization/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
enzyme in the presence of manganese and UDP, hanging drop vapor diffusion method, using 100 mM Tris-HCl (pH 8.0), 1 M NaCl, 15% (v/v) MPD, and 5% (w/v) polyethylene glycol 6000
hanging drop vapor diffusion method, using 100 mM imidazole (pH 6.5) and 750 mM sodium acetate or 100 mM HEPES buffer (pH 8.0), 100mM serinol, 1.0 M NaCl, 5% (w/v) PEG6000, and 10% 2,4-methanepentadiol; purified recombinant detagged enzyme in complex xylobiose, hanging drop vapor diffusion method, mixing of protein solution containing 10 mg/ml protein, 10 mM MnCl2, 10 mM UDP, and 10 mM xylobiose, with a reservoir solution containing 100mM HEPES, pH 8.0, 100mM serinol, 1.0 M NaCl, 5% PEG 6000, and 10% 2-methyl-2,4-pentanediol, crystals of enzyme mutants D318N and D211N protein in complex with UDP-Gal, by hanging drop vapor diffusion method, using a protein solution containing 10 mg/ml protein, 10 mM MnCl2, and 10 mM UDP-Gal, with the precipitating solution containing 100 mM HEPES, pH 8.0, 1.0 M NaCl, 5% PEG 6000, and 10% 2-methyl-2,4-pentanediol, X-ray diffraction structure determination and analysis
purified recombinant detagged wild-type and truncated enzymes, hanging drop vapor diffusion method, mixing of 15 mg/ml protein solution with reservoir solution containing 100 mM imidazole, pH 6.5, 5 mM MnCl2, and 750 mM sodium acetate, 18°C, X-ray diffraction structure determination and analysis, molecular replacement using the Drosophila melanogaster beta4GalT7 crystal structure, PDB ID 3LW6, as a search model. For crystal complexes, tetragonal crystals are soaked in the same pH 6.5 reservoir solution containing 15% 2-methyl-2,4-pentanediol at 18 °C for 20 h followed by a brief soak in 100 mM Tris, pH 8.0, 750 mM sodium acetate, 15% 2-methyl-2,4-pentanediol, 5 mM MnCl2, and 5 mM UDP-Gal at room temperature. The monoclinic crystals are obtained within 3 days using 100 mM Tris, pH 8.5, and 8% PEG 8000 as a reservoir solution by mixing it with 20 mg/ml beta4GalT7DELTA81 in 10 mM MES (pH 6.5), 150 mM NaCl, 5 mM MnCl2, and 5 mM UDP-galactose at 18 °C
-
GENERAL STABILITY
ORGANISM
UNIPROT
LITERATURE
dialysis against detergent-free buffer, +/- 0.25 M KCl inactivates, dialysis against 1% Nonidet P-40 and 0.25 M KCl restores activity, even after a period of 18 h in the absence of detergent
-
Nonidet P-40 stabilizes solubilized enzyme
-
repeated freezing and thawing, collagenase treatment and sonication result in a significant loss of activity
-
STORAGE STABILITY
ORGANISM
UNIPROT
LITERATURE
-17°C, concentrated enzyme preparation of 1 mg/ml, at least 6 months
-
Purification/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
glutathione Sepharose column chromatography
-
glutathione Sepharose column chromatography; recombinant soluble GST-tagged mutant enzyme from Escherichia coli strain BL21(DE3)
glutathione-Sepharose column chromatography
-
lactose affinity column chromatography, UDP-agarose column chromatography, and amylose column chromatography
-
nickel-iminodiacetic acid column chromatography
-
purification of maltose-binding protein-beta1,4-GalT7 fusion protein with an amylose column
-
recombinant N-terminally His6-tagged enzyme by affinity chromatography, and cleavage of the tag by TEV protease
solubilized and partially purified, affinity chromatography
-
Cloned/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
cloning and expression of human membrane beta1,4-GalT7 in HeLa cells, expression of soluble form as a fusion protein with maltose-binding protein in Escherichia coli
-
expressed as a GST-fusion protein in Escherichia coli and as Myc-tagged fusion proteins in HeLa cells; expressed in Escherichia coli BL21(DE3) cells, HeLa cells and CHO pgsB-618 cells
-
expressed in Escherichia coli BL21(DE3) cells
-
expressed in Escherichia coli BL21(DE3) cells; gene B4GALT7, recombinant expression of GST-tagged wild-type and mutant enzymes in CHOpgsB-618 cells, recombinant expression of the soluble GST-tagged mutant enzyme in Escherichia coli strain BL21(DE3)
expressed in Escherichia coli BL21(DE3)pLysS cells
-
expressed in Escherichia coli Rosetta(DE3)pLysS cells
expressed in in CHO618 cells as membrane protein and in Escherichia coli as soluble protein fused to maltose-binding protein; mutated beta1,4-GalT7s are expressed as soluble maltose-binding protein fusions in which the N-terminal cytoplasmic domain, the transmembrane segment and the stem region, which precede the catalytic domain and correspond to amino acids 1-81, are deleted
-
expression in Cos-1 cells
-
expression in Escherichia coli
expression in galactosyltransferase-deficient CHO618 cells
-
expression in Pichia pastoris
expression in Spodoptera frugiperda Sf9 cells
-
expression in Spodoptera frugiperda SF9 cells as prot-A-beta4-GalT fusion protein
-
expression in transgenic mice
-
expression in Xenopus laevis oocytes
-
expression of a hybrid enzyme (called xylGalT), consisting of the N-terminal domain of Arabidopsis thaliana xylosyltransferase and the catalytic domain of human beta-1,4-galactosyltransferase I (GalT) in tobacco causes a sharp reduction of N-glycans with potentially immunogenic corebound xylose (Xyl) and fucose (Fuc) residues
-
gene B4GALT7, recombinant expression of N-terminally His6-tagged enzyme
quantitative enzyme expression analysis by RT-PCR
-
transient expression in mouse fibroblast L cells and chinese hamster ovary K-1 cells
-
truncated enzyme form is expressed in Escherichia coli BL21(DE3) cells
-
EXPRESSION
ORGANISM
UNIPROT
LITERATURE
beta-1,4-GalT I mRNA reaches peaks at 2 weeks after sciatic nerve crush, in situ hybridization shows that at day 1 after sciatic nerve crush, the expression levels of beta-1,4-GalT I mRNA is strong at the crush site, and decreases gradually from crush site to the distal segments, the expression of beta-1,4-GalTI mRNA is related to the injury site and injury time in peripheral nervous system; beta-1,4-GalT V mRNA reaches peaks at 2 weeks after sciatic nerve crush, in situ hybridization shows that at day 1 after sciatic nerve crush, the expression levels of beta-1,4-GalT V mRNA is strong at the crush site, and decreases gradually from crush site to the distal segments
-
beta-1,4-GalT-I is strongly induced in the ventral midbrain by intranigral injection of lipopolysaccharide, significant increase in beta-1,4-GalT-I mRNA at 8 h after focal injection of lipopolysaccharide, and lastes to 18 h, then decreases gradually
-
beta-1,4-GalT-I mRNA is significant increased as early as 2 h after lipopolysaccharide stimulation (1 microM/ml), upregulation in a time- and concentration-dependent manner
-
both anti-TNFR1 and anti-TNFR2 antibodies suppressed beta-1,4-GalT I mRNA expression induced by tumor necrosis factor-alpha or lipopolysaccharide
decreasing of the expression of GalT I in hepatoma cells reduce the ability of tumor formation in vivo and inhibits hepatitis B virus-encoded protein HBx-induced cell cycle progression
-
GalT I is highly expressed in hepatocellular carcinoma and transcriptionally up-regulated by hepatitis B virus-encoded HBx, and functions as a positive growth regulator in hepatoma cells
-
in injured spinal cords, enzyme is significantly increased after 8 h, beta-1,4-GalT-I mRNA reaches the peak at 1 day after spinal cord contusion, then gradually reduced from day 5 to day 7, recovers to the baseline level at 14 day
-
the beta-1,4-GalT I mRNA reaches peaks at 2 weeks after sciatic nerve crush and 3 days after sciatic nerve transection in a dose-dependent manner, in inflammation, lipopolysaccharide administration affects beta-1,4-GalT I mRNA expression in sciatic nerve in a time- and dose-dependent manner, and beta-1,4-GalT I mRNA is expressed mainly in Schwann cells
-
the expression level of beta-1,4-GalT I mRNA in cultured type-2 astrocytes is dose-dependent compared with the control group, it decreases at 0.1 ng/ml tumor necrosis factor-alpha, reaches at a peak at 1 ng/ml and then restores to normal level at 5 ng/ml. The expression in cultured type-2 astrocytes is time-dependent, it increases from 0.5 h, peaks at 4 h, then it decreases gradually to normal level after exposure to 1 ng/ml tumor necrosis factor-alpha. Lipopolysaccharide induces beta-1,4-GalT I mRNA expression in type-2 astrocytes in a time- and dose-dependent manner
ENGINEERING
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
D211N
mutant with negligible catalytic activity; site-directed mutagenesis, the catalytic base Asp211 is mutated to Asn residue, inactive mutant, substrate-bound crystal structure analysis
D318N
mutant with negligible catalytic activity
D163A
-
inactive
D165A
-
inactive
D165E
-
the apparent Km values of the D165E mutant toward UDP-galactose and 4-methylumbelliferyl-O-beta-D-xylopyranoside are about 3.8 and 5.5fold, respectively, higher than the wild type enzyme
D228A
-
inactive
D228E
-
the mutant expressed in HeLa cells retains about 40% activity of the wild type enzyme
D230A
-
the mutant shows increased Km values towards UDP-galactose and 4-methylumbelliferyl-O-beta-D-xylopyranoside compared to the wild type enzyme
DELTA1-81
-
deletion construct is enzymatically active with Km values similar to wild-type towards donor and acceptor substrate, kcat higher compared to full-length wild-type
DELTA1-81/A186D
-
kcat values similar to wild-type DELTA1-81 construct, Km values towards donor and acceptor substrates increased compared to wild-type
DELTA1-81/L206P
-
in contrast to full-length mutant L206P this deletion mutant is enzymatically active, kcat values similar to wild-type DELTA1-81 construct, Km values towards donor and acceptor substrates increased compared to wild-type
DELTA1-81/R270C
-
kcat values similar to wild-type DELTA1-81 construct, Km values towards donor and acceptor substrates increased compared to wild-type
E227D
-
the mutant displays similar apparent Km values toward both donor and acceptor substrates compared with the wild type enzyme
F221A
-
the mutant shows increased Km values towards UDP-galactose and 4-methylumbelliferyl-O-beta-D-xylopyranoside compared to the wild type enzyme
F221Y
-
the mutant shows increased Km values towards UDP-galactose and 4-methylumbelliferyl-O-beta-D-xylopyranoside compared to the wild type enzyme
G223a
-
the mutant is about 40% less active than the wild type enzyme
G225A
-
the mutant does not display any in vitro activity
H195A
site-directed mutagenesis, the mutant shows reduced activity compared to the wild-type enzyme; the mutant shows reduced activity compared to the wild type enzyme
H195Q
site-directed mutagenesis, the mutant shows reduced activity compared to the wild-type enzyme; the mutant shows reduced activity compared to the wild type enzyme
H195R
site-directed mutagenesis, the mutant shows reduced activity compared to the wild-type enzyme; the mutant shows reduced activity compared to the wild type enzyme
L206A
-
mutant shows similar enzymatic activity compared to wild-type, Km towards donor substrate similar to wild-type, increased towards acceptor substrate
R226A
site-directed mutagenesis, the mutant shows reduced activity compared to the wild-type enzyme; the mutant shows reduced activity compared to the wild type enzyme
R226K
site-directed mutagenesis, the mutant shows reduced activity compared to the wild-type enzyme; the mutant shows reduced activity compared to the wild type enzyme
R270A
site-directed mutagenesis, the mutant shows reduced activity compared to the wild-type enzyme; the mutant shows reduced activity compared to the wild type enzyme
R270K
site-directed mutagenesis, the mutant shows reduced activity compared to the wild-type enzyme; the mutant shows reduced activity compared to the wild type enzyme
V164A
-
the mutant shows increased Km values towards UDP-galactose and 4-methylumbelliferyl-O-beta-D-xylopyranoside compared to the wild type enzyme
W222A
-
the mutant shows decreased Km value towards UDP-galactose compared to the wild type enzyme
W222F
-
the mutation has no significant effect on the Km value toward donor or acceptor substrate
W224H
-
the mutant is able to sustain decorin glycosaminoglycan chain substitution but not glycosaminoglycan synthesis from exogenously added xyloside
Y194A
inactive; site-directed mutagenesis, inactive mutant
Y194F
inactive; site-directed mutagenesis, inactive mutant
Y196A
inactive; site-directed mutagenesis, inactive mutant
Y196F
site-directed mutagenesis, the mutant shows reduced activity compared to the wild-type enzyme; the mutant shows reduced activity compared to the wild type enzyme
Y199A
inactive; site-directed mutagenesis, inactive mutant
Y199F
site-directed mutagenesis, the mutant shows reduced activity compared to the wild-type enzyme; the mutant shows reduced activity compared to the wild type enzyme
Y306G/W307G
-
double-mutant deprives the galactosyltransferase activity of GalT I, the point mutation abolishes the ability of GalT I to promote cell cycle progression of hepatoma cells
additional information
Renatured/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
100 mg of sulfonated protein are folded for 48 h in folding solution containing oxido-shuffling agents and 500 mM arginine-HCl
APPLICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
drug development
the enzyme is a target for the development of enzyme inhibitors as regulators of glycosaminoglycan synthesis in therapeutics